Genzyme Expands Global Infrastructure for Manufacturing, R&D
European Investments to Support Growth of Antibody, Protein Products
The facilities include a new bio-manufacturing plant in Geel, Belgium for the production of monoclonal antibodies and proteins; expansion of Genzyme's manufacturing centers in Waterford, Ireland and Haverhill, UK; and creation of an antibody discovery research facility in Cambridge, United Kingdom.
Genzyme also announced that in addition to producing humanized monoclonal antibodies at its Geel plant, this facility will be used to meet the anticipated demand for Myozyme® (alglucosidase alfa), an enzyme replacement therapy currently under review with U.S. and European regulatory authorities for the treatment of Pompe disease. Production in Geel will augment that at Genzyme's flagship protein manufacturing facility in Boston (Allston), Massachusetts.
Genzyme has a total of seven manufacturing sites in Europe, including a small molecule production site in Liestal, Switzerland, a polyclonal bio-manufacturing site in Lyon, France, and diagnostic manufacturing facilities in Kent, UK and Rüsselsheim, Germany.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous